The chemosensitivity of nodal metastases in recurrent epithelial ovarian cancer

Purpose: In this study, we compared second-line chemotherapy effects of nodal metastases with other metastases sites. Methods: The medical records of 44 women with recurrent ovarian cancer who received second-line chemotherapy were retrospectively reviewed. Results: Median age at the time of second-line chemotherapy was 55 years (range: 31-74). Recurrent sites were as follows: 29 patients had a solitary site (abdominal cavity: 8; lymph node: 3; pelvic cavity: 10; liver: 4; lung: 4) and 15 patients had multiple sites In total, the response rate was 30% (CR: 8, PR: 5). The response rate in sensitive cases was higher than in refractory/resistant cases (50% vs 5% p = 0.002). However, age, chemotherapy regimen, histologic type and number of diseases were not related with chemotherapy effect. In all diseases, response rate tended to be higher in lymph node disease than in the others (44% vs 27%). In both sensitive and refractory/resistant cases, response rate tended to be higher in lymph node disease. Conclusion: The response rate for lymph node diseases tended to be relatively high. Further study analyzing survival will be required to conclude the chemotherapy effect.

Second-line chemotherapy; Recurrence; Lymph node; Recurrent site

[1] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y. et al.: “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer”. N. Engl. J. Med., 1996, 334, 1.

[2] Eisenkop S.M., Friedman R.L., Spirtos N.M.: “The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma”. Cancer, 2000, 88, 144.

[3] Scarabelli C., Gallo A., Carbone A.: “Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma”. Gynecol. Oncol., 2001, 83, 504.

[4] Zang R.Y., Li Z.T., Tang J., Cheng X., Cai S.M., Zhang Z.Y. et al.: “Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?”. Cancer, 2004, 100, 1152.

[5] Onda T., Yoshikawa H., Yasugi T., Yamada M., Matsumoto K., Taketani Y.: “Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection”. Br.

J. Cancer, 2005, 92, 1026.

[6] Chi D.S., McCaughty K., Diaz J.P., Huh J., Schwabenbauer S., Hummer A.J. et al.: “Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma”. Cancer, 2006, 106, 1933.

[7] Harter P., du Bois A., Hahmann M., Hasenburg A., Burges A., Loibl S. et al.: “Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial”. Ann. Surg. Oncol., 2006, 13, 1702.

[8] Bristow R.E., Puri I., Chi D.S.: “Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis”. Gynecol. Oncol., 2009, 112, 265.

[9] Benedetti Panici P., Perniola G., Angioli R., Zullo M.A., Manci N., Palaia I. et al.: “Bulky lymph node resection in patients withrecurrent epithelial ovarian cancer: impact of surgery”. Int. J. Gynecol. Cancer, 2007, 17, 1245.

[10] Blanchard P., Plantade A., Pages C., Afchain P., Louvet C., Tournigand C. et al.: “Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors”. Gynecol. Oncol., 2007, 104, 41.

[11] Santillan A., Karam A.K., Li A.J., Giuntoli R. 2nd, Gardner G.J., Cass I., Karlan B.Y., Bristow R.E.: “Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer”. Gynecol. Oncol., 2007, 104, 686.

[12] Legge F., Petrillo M., Adamo V., Pisconti S., Scambia G., Ferrandina G.: “Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome”. BMC Cancer, 2008, 8, 367.

[13] Morice P., Joulie F., Rey A., Atallah D., Camatte S., Pautier P. et al.: “Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy”. Eur. J. Gynaecol. Oncol., 2004, 25, 169.

[14] Hanahan D., Weinberg R.A.: “The hallmarks of cancer”. Cell, 2000, 100, 57.

[15] Bhowmick N.A., Neilson E.G., Moses H.L.: “Stromal fibroblasts in cancer initiation and progression”. Nature, 2004, 432, 332.

[16] Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R. et al.: “Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion”. Cell, 2005, 121, 335.

[17] Di Re F., Fontanelli R., Raspagliesi F., Di Re E.: “Pelvic and paraaortic lymphadenectomy in cancer of the ovary”. In: BurghartE., Monaghan J. (eds.). Clinical Obstetrics and Gynecology, vol. 3. London: Bailliere Tindall, 1989, 131.

[18] Burghardt E., Pickel H., Lahousen M., Stettner H.: “Pelvic lymphadenectomy in operative treatment of ovarian cancer”. Am. J. Obstet. Gynecol., 1986, 155, 315.

[19] Tulusan A., Adam R., Reinhard M., Atanasov N., Thyselius D., Merkle E.: “Lymph node metastasis in epithelial ovarian cancer”. In: Sharp F., Mason W., Leake R. (eds.). Ovarian cancer: biological and therapeutic challenges. London: Chapman & Hall, 1990, 443.

[20] Kusumoto H., Maehara Y., Kusumoto T., Anai H., Akazawa K., Sugimachi K.: “Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer”. Eur. J. Surg. Oncol., 1988, 14, 685.

[21] Uzan C., Morice P., Rey A., Pautier P., Camatte S., Lhomme C. et al.: “Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes”. Ann. Surg. Oncol., 2004, 11, 658.